Ishida Y, Mukai K, Yajima S, Takayama J, Shimoyama M, Konda C, Watanabe S, Ohira M
Division of Pediatrics, National Cancer Center Hospital, Tokyo, Japan.
Int J Hematol. 1991 Jun;54(3):241-9.
A retrospective clinicopathological study was performed on 149 patients who developed malignant lymphoma at under 20 years of age and were diagnosed and treated at the National Cancer Center Hospital between 1962-1986. Using the Japanese Lymphoma Study Group classification (and Working Formulation), we reclassified the 84 evaluable tissue specimens as follows: follicular large and mixed lymphoma (two cases), diffuse lymphoblastic lymphoma (40 cases), Burkitt's lymphoma (small noncleaved, SNC) (12 cases), diffuse large and mixed cell lymphoma (25 cases), and unclassified (five cases). The age of the patients ranged from 6 months to 20 years, with a median of 11 years. The clinical characteristics were found to depend upon the histological diagnosis, as reported previously. To evaluate the influence of various clinical and morphological parameters on survival, univariate analysis was performed for each histological subtype. In lymphoblastic lymphoma, patients with a mediastinal mass had significantly earlier development of leukemic conversion and a shorter survival than patients without a mass. Because of the small number of patients and their short survival, no significant prognostic factors were found in Burkitt's lymphoma (SNC). In large and mixed cell lymphoma, response to therapy was the most significant prognostic factor. As therapy became more intense and systematic throughout the study period, the complete remission rate and survival improved steadily. Autopsy findings confirmed that lymphoblastic lymphoma and Burkitt's lymphoma (SNC) spread systemically earlier than large and mixed cell lymphoma.
对149例20岁以下发生恶性淋巴瘤且于1962年至1986年间在国立癌症中心医院确诊并接受治疗的患者进行了回顾性临床病理研究。采用日本淋巴瘤研究组分类法(及工作分型法),我们将84份可评估的组织标本重新分类如下:滤泡性大细胞和混合性淋巴瘤(2例)、弥漫性淋巴细胞淋巴瘤(40例)、伯基特淋巴瘤(小无裂细胞型,SNC)(12例)、弥漫性大细胞和混合细胞淋巴瘤(25例)以及未分类(5例)。患者年龄从6个月至20岁不等,中位年龄为11岁。如先前报道,临床特征取决于组织学诊断。为评估各种临床和形态学参数对生存的影响,对每种组织学亚型进行了单因素分析。在淋巴细胞淋巴瘤中,有纵隔肿块的患者白血病转化出现得明显更早,生存期也比无肿块的患者短。由于伯基特淋巴瘤(SNC)患者数量少且生存期短,未发现显著的预后因素。在大细胞和混合细胞淋巴瘤中,对治疗的反应是最显著的预后因素。在整个研究期间,随着治疗变得更加积极和系统,完全缓解率和生存率稳步提高。尸检结果证实,淋巴细胞淋巴瘤和伯基特淋巴瘤(SNC)比大细胞和混合细胞淋巴瘤更早发生全身扩散。